

02-30000-12

Original Effective Date: 08/15/10

Reviewed: 07/25/19

Revised: 08/15/19

Subject: Bronchial Thermoplasty

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Updates			

DESCRIPTION:

Bronchial thermoplasty (BT) is a procedure that delivers thermal energy to the airways via a flexible bronchoscope to ablate and reduce the mass of airway smooth muscle. Bronchial thermoplasty is intended as a supplemental treatment for patients with severe persistent asthma (i.e., steps 5 and 6 in the [stepwise approach to care](#)).

Bronchial thermoplasty procedures are performed on an outpatient basis with moderate sedation, and last approximately one hour each. During the procedure, a standard flexible bronchoscope is placed through the patient's mouth or nose into the most distal targeted airway and a catheter is inserted into the working channel of the bronchoscope. After placement, the electrode array in the top of the catheter is expanded and radiofrequency energy is delivered from a proprietary controller and used to heat tissue to 65 degrees Centigrade over a 5 mm area. The positioning of the catheter and application of thermal energy is repeated several times in contiguous areas along the accessible length of the airway. At the end of the treatment session, the catheter and bronchoscope are removed. A course of treatment consists of 3 separate procedures in different regions of the lung, scheduled approximately 3 weeks apart.

In April 2010, the Alair Bronchial Thermoplasty System (Asthmatx, Inc., Sunnyvale, CA) was approved by the FDA through the premarket approval (PMA) process for use in adults with severe and persistent asthma whose symptoms are not adequately controlled with inhaled corticosteroids and long-acting beta agonists. Use of the treatment is contraindicated in patients with implantable devices and those with sensitivities to lidocaine, atropine or benzodiazepines. It should also not be used while patients are experiencing an asthma exacerbation, active respiratory infection, bleeding disorder, or within 2 weeks of making changes in their corticosteroid regimen. The same area of the lung should not be treated more than once with bronchial thermoplasty.

POSITION STATEMENT:

Bronchial thermoplasty for the treatment of asthma and all other indications is considered **experimental or investigational**. There is insufficient clinical evidence published in the peer-reviewed literature regarding safety and long-term efficacy of bronchial thermoplasty on health outcomes.

BILLING/CODING INFORMATION:

CPT Coding:

31660	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe (investigational)
31661	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes (investigational)

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products:

No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline reviewed date.

DEFINITIONS:

Stepwise approach to care: Guidelines from the National Heart, Lung and Blood Institute (NHLBI) define 6 pharmacologic steps for the treatment of asthma (step 1 for intermittent asthma, and steps 2 – 6 for persistent asthma) for individual's ≥ 12 years of age.

The preferred daily medications:

Step 1: short-acting beta-agonists as needed;

Step 2: low-dose inhaled corticosteroids (ICS);

Step 3: ICS and long-acting beta-agonists (LABA) or medium-dose ICS;

Step 4: medium dose ICS and LABA;

Step 5: high-dose ICS and LABA; **AND**

Step 6: high-dose ICS and LABA, and oral corticosteroids.

RELATED GUIDELINES:

None applicable.

OTHER:

None applicable.

REFERENCES:

1. American College of Allergy, Asthma & Immunology Statement on bronchial thermoplasty, 01/01/15.
2. American College of Chest Physicians. Coverage and Payment for Bronchial Thermoplasty for Severe Persistent Asthma. May 2014.
3. Arrigo R, Failla G, Scichilone N, et al. How effective and safe is bronchial thermoplasty in "real life" asthmatics compared to those enrolled in randomized clinical trials? *Biomed Research International*. 2016; 2016: 9132198.
4. Asthma and Allergy Foundation of America. Letter to FDA re: Alair Bronchial Thermoplasty System (10/18/2009). Assessed 07/16/14.
5. Bezzi M, Solidoro P, Patella V et al. Bronchial thermoplasty in severe asthma: food for thoughts. *Minerva Medica* 2014; 105 (3 Suppl. 2): 7-13.
6. Blue Cross Blue Shield Association Medical Policy Reference Manual 7.01.127 Bronchial Thermoplasty, 07/19.
7. Bicknell S, Chaudhuri R, Lee N, et al. Effectiveness of bronchial thermoplasty in severe asthma in 'real life' patients compared with those recruited to clinical trials in the same centre. *Therapeutic Advances in Respiratory Disease* 2015; 9(6):267-271.
8. Boulet LP, Laviolette M. Is there a role for bronchial thermoplasty in the treatment of asthma? *Can Respir J*. 2012 May-Jun;19 (3):191-2.
9. Brown R, Wizeman W, Danek, C, Mitzner W. Effect of Bronchial Thermoplasty on Airway Closure. *Clin Med Circ Respirat Pulm Med*. 2007 October 12; 1:1-6.
10. Burn J, Sims AJ, Keltie K, et al. Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. *Journal of Asthma* 2016 Dec 1.
11. Cangelosi MJ, Ortendahi JD, Meckley LM et al. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled severe, persistent asthma. *Expert Review of Pharmacoeconomics & Outcomes Research* 2015; 15(2): 357-64.
12. Castro M, Rubin AS, Laviolette M et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. *American Journal of Respiratory and Critical Care Medicine* 2010; 181(2): 116-124.
13. Castro M, Rubin A, Laviolette ML et al. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. *Annals of Allergy, Asthma & Immunology* 2011; 107(1): 65-70.
14. Chakir J, Haj-Salem I, Gras D et al. Effects of Bronchial Thermoplasty on Airway Smooth Muscle and Collagen Deposition in Asthma. *Annals of American Thoracic Society* 2015; 12(11): 1612-1618.
15. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *European Respiratory Journal* 2014; 43(2):343-373.
16. Chupp G, Laviolette M, Cohn L et al. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. *European Respiratory Journal* 2017 August; 50(2).
17. Cox G, Thomson NC, Rubin AS et al. Asthma control during the year after bronchial thermoplasty. *New England Journal of Medicine* 2007; 356(13): 1327-1337.
18. Dheda K, Koegelenberg CFN, Esmail A et al. Recommendations for the use of bronchial thermoplasty in the management of severe asthma. *South African Medical Journal* 2015; 150(9): 726-732.
19. d'Hooghe JNS, van den Berk IAH, Annema JT et al. Acute Radiological Abnormalities after Bronchial Thermoplasty: A Prospective Cohort Trial. *Respiration* 2017; 94(3): 258-262.

20. Du Rand IA, Barber PV, Goldring J, Lewis RA, Mandal S, Munavvar M, Rintoul RC, Shah PL, Singh S, Slade MG, Woolley A, British Thoracic Society Interventional Bronchoscopy Guideline Group. British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. *Thorax* 2011; 66 (11): 1014-1015.
21. Folch E, Mehta AC. Airway Interventions in the Tracheobronchial Tree. *Semin Respir Crit Care Med*. 2008; 29(4):441-452.
22. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA); Updated 2019.
23. Gildea TR, Khatri SB, Castro M. Bronchial thermoplasty: a new treatment for severe refractory asthma. *Cleve Clin J Med*. 2011 Jul; 78(7):477-85.
24. Krmisky W, Sobieszczyk MJ, Sarkar S. Thermal ablation for asthma: current status and technique. *Journal of Thoracic Disease* 2017 2017; 9 (Suppl 2): S104-S109.
25. Langton D, Sha J, Ing A et al. Bronchial thermoplasty: activations predict response. *Respiratory Research* 2017 July; 18(1): 134.
26. Mayse ML, et al. Clinical Pearls for Bronchial Thermoplasty. *J Bronchol* 2007; 14:115-123.
27. National Guideline Clearinghouse. Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of asthma. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Jan. 69 p. [83 references].
28. National Heart Lung and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, Revised Sept 2012.
29. National Institute for Health and Care Excellence. Bronchial thermoplasty for severe asthma. *Interventional procedures guidance [IPG635]*, 2019.
30. O'Reilly A, Lane S. What is the role of bronchial thermoplasty in the management of severe asthma? *Therapeutic Advances in Respiratory Disease* 2018 Jan-Dec; 12:1753466618792410.
31. Pavord ID, Cox G, Thomson C et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. *American Journal of Respiratory and Critical Care Medicine* 2007; 176(12): 1185-1191.
32. Pavord ID, Thomson NC, Niven RM, et al. Safety of bronchial thermoplasty in patients with severe refractory asthma. *Ann Allergy Asthma Immunol*. 2013 ; 111(5):402-407.
33. Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, Pavord ID, McCormack D, Laviolette M, Shargill NS, Cox G, the AIR Trial Study Group. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. *BMC Pulm Med* 2011;11(1):8.
34. Thomson NC, Chaudhuri R, Spears M. Emerging therapies for severe asthma. *BMC Med*. 2011 Sep 6; 9:102.
35. Torrego A, Sola I, Munoz AM et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. *Cochrane Database Systematic Review* 2014 Mar 3; (3): CD009910. doi: 10.1002/14651858.CD009910.pub2.
36. U.S. Food and Drug Administration. Asthmatx, Inc. Alair Bronchial Thermoplasty System – P080032, 04/27/10.
37. Wahidi NM, Kraft M. Bronchial thermoplasty for severe asthma. *American Journal of Respiratory and Critical Care* 2012; 185(7): 709-14.
38. Wechsler ME, Laviolette M, Rubin A et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. *Journal of Allergy and Immunology* 2013; 132(6): 1295-1302.
39. Zafari Z, Sadatsafavi M, Marra CA et al. Cost-effectiveness of bronchial thermoplasty, Omalizumab, and standard therapy for moderate-to-severe allergic asthma. *PLoS One* 2016; 11(1): e0146003.

40. Zein JG, Menegay MC, Singer ME et al. Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma. *Journal of Asthma* 2016; 53(2): 194-200.
41. Zervas E, Samitas K, Papaioannou AI et al. An algorithmic approach for the treatment of severe uncontrolled asthma. *EJR Open Research* 2018 March; 4(1).

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the BCBSF Medical Policy & Coverage Committee on 07/25/19.

GUIDELINE UPDATE INFORMATION:

08/15/10	New Medical Coverage Guideline.
08/15/11	Annual review; position statement unchanged; references updated.
01/01/12	Annual HCPCS coding update: added 0276T and 0277T.
09/15/12	Annual review; position statement unchanged; references updated.
01/01/13	Annual HCPCS coding update: added 31660 and 31661; removed 0276T and 0277T.
09/15/13	Scheduled review; position statement unchanged; Program Exceptions section updated; references updated.
09/15/14	Annual review; position statement unchanged; Program Exceptions section updated; references updated.
11/01/15	Revision: ICD-9 Codes deleted.
09/15/16	Review; no change in position statement. Updated description and references.
03/06/17	Updated program exceptions.
08/15/17	Review; no change in position statement. Updated references.
11/15/17	Revised position statement; added and all indications.
09/15/18	Review; revised position statement. Updated references.
08/15/19	Review; no change in position statement. Updated references.